Oxford-AstraZeneca vaccine shows positive immune response in early study

A potential coronavirus vaccine developed by Oxford University in the U.K. has produced a strong immune response in a large, early-stage human trial, according to newly-released data published Monday in the medical journal, The Lancet. CNBC's Meg Tirrell reports. Subscribe to CNBC PRO for access to investor and analyst insights on vaccine and more: https://cnb.cx/2BT2E7y

A potential coronavirus vaccine developed by Oxford University with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet.

The researchers are calling their experimental vaccine ChAdOx1 nCoV-19 (AZD1222). It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees. The phase one trial had more than 1,000 participants in people ages 18 to 55.

AstraZeneca’s shares were down 2.5% in midday trading.

The researchers said the vaccine produced antibodies and killer T-cells to combat the infection that lasted at least two months. Neutralizing antibodies, which scientists believe is important to gain protection against the virus, were detected in participants. The T-cell response did not increase with a second dose of the vaccine, they said, which is consistent with other vaccines of this kind.

“The immune system has two ways of finding and attacking pathogens — antibody and T cell responses,” Oxford professor Andrew Pollard said in a release. “This vaccine is intended to induce both, so it can attack the virus when it’s circulating in the body, as well as attacking infected cells. We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period.”

The vaccine was found to be well-tolerated and there were no serious adverse events, according to the researchers. Fatigue and headache were the most commonly reported, they said. Other common side effects included pain at the injection site, muscle ache, chills and a fever.

Adrian Hill, director of Oxford’s Jenner Institute, told CNBC on Monday the strong immune response means the vaccine is more likely to provide protection against the virus, though nothing is guaranteed. He said scientists hope to begin human trials in the United States in a few weeks.

“We are using single-dose and two-dose of the vaccine,” he told “Worldwide Exchange.” “It looks like both give useful immune responses even though after two doses we see stronger immune responses.”

The potential vaccine is one of at least 100 being developed across the world for Covid-19, which has infected more than 14 million people worldwide and killed at least 606,206, according to data compiled by Johns Hopkins University. At least 23 of the vaccine candidates are already in human trials, according to the World Health Organization.

Last week, biotech firm Moderna released promising data on its vaccine trial, saying it generated a “robust” immune response. That trial included 45 healthy participants and was run by the National Institutes of Health.

Earlier this month, pharmaceutical giant Pfizer, alongside German drugmaker BioNTech, released positive results from its closely watched early-stage human trial. The company said its vaccine produced neutralizing antibodies in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data.

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

For info on the best credit cards go to CNBC Select:
https://www.cnbc.com/select/best-credit-cards/

#CNBC
#CNBCTV

Noticias relacionadas:

42 comentarios:

CatMom
CatMom:
Terrific! I had heard that this was in a Phase 1 trial, & it seems this may indeed be what all the scientists have been working toward.
TheMilpitasguy
TheMilpitasguy:
I wonder how much clinical trials testing went into side effects generated when the polio vaccine first came out.
Conn_Man_24
Conn_Man_24:
They may give emergency authorization in October or November. Like giving it to health care workers and at risk people first. When it’s released publicly it won’t stop the spread in one week it will take time for enough people who got the vaccine to stop the spread.
Michaelin
Michaelin:
Praise Him..😇💜
May this vaccine , would be success before the end of the year
David Ellis
David Ellis:
It's a great 🌄 & Happy Monday with the lovely Meg !
Inc n
Inc n:
WHO, vaccine developers and manufacturers should show some more responsibility. In this severe state of pandemic (where many kids lose their parents, parents lose their kids, etc) these medical bodies should fast track vaccine development and should not rely on conventional easy-going techniques. Mostly these manufacturers are much focused on the share market than the development.

Lack of coordination is clearly visible, only business and competition are going on.
PEPA GAMING
PEPA GAMING:
Great.. effort
PlayingTheObjective5820
PlayingTheObjective5820:
I’m not going to lie, as a senior in HS soon to go to college, other than ending school early this virus hasn’t effected me at all. Got my stim check, got a job, graduated yesterday, and am off to school on the 19th
Li Ly
Li Ly:
And pls don't forget to research and
thoroughly analyze what else that liquid will induce in a human body years later ? Maybe cancer, thrombosis, infertility ,aplastic anemia , blindness , seizures , multiple sclerosys and so on ? Isn't that important ?
Vidyasagar Buddha
Vidyasagar Buddha:
Hope the world do not look over CHINESE CHEAP medicine this time :-)
Marian
Marian:
Just imagine how big and small countries will fight for this vaccine..
King Don Julion
King Don Julion:
🔥🔥🔥
Dwayne Smith
Dwayne Smith:
I loved working at AstraZeneca was one of the best experience I've ever had as far as learning new things every day. Im not surprised by this they have some of the best scientist in the world working there I've witness this Hands-On.
hrcutz
hrcutz:
Screw the stocks, where’s the cure?
Biju vithura
Biju vithura:
great news
1...... 2. ...... 3. ......
unanimous reporting
unanimous reporting:
you take it let us know how you feel in 10-15 years
Black Baron
Black Baron:
1:00 Going UP! YES!
Student Helper Kamal
Student Helper Kamal:
Serum institute of India will be help you for production Million doses ,, World is a family 😊
U.P. dan
U.P. dan:
Russia already has a tested vaccine. I want that one, it’s hugely cheaper and more effective.
Michael Hall
Michael Hall:
All I can think of is their drug commercial.

*AstraZeneca* *may* *be* *able* *to* *help* hopefully...
Raya Raya
Raya Raya:
When will it be available for generals?
Jason Ludwig
Jason Ludwig:
Trading bets on unicorn blood. Perfect.
Càbdulaahi Gaabow
Càbdulaahi Gaabow:
Better potential trial we hope we can do better what we are looking to human trial assistance not less deteriorations of our humankind.
Hari Harsha
Hari Harsha:
Always saying In media only wen I'll cm out ??? Everyone money minded people in society sad poor people
Tracy Garner
Tracy Garner:
Very nervous this was tested on mice or went straight to humans? No telling how long until we see the long term effects.
bpatton1234
bpatton1234:
take it if you want to but don't sue them if something go's wrong.....OK
ruben d
ruben d:
So when are we suppose to get that 2K check? Quit playin
MG
MG:
Don’t worry world. Britain’s got it 🇬🇧
Barbara Pietra
Barbara Pietra:
Such BS...
Robert Giffin
Robert Giffin:
Ok but what is in it.What is wrong with herd immune.easyest way to fight the virus.
Cheryl Alikhani
Cheryl Alikhani:
Test it on Trump.
2ndAmendment
2ndAmendment:
I'll pass. Thanks anyways though. If this mutates to a new strain, like the flu does, 😂
joeybullet_222
joeybullet_222:
Dummies will want one out of fear. Lmao
taco tuesday
taco tuesday:
why should i give af about their stock?
CherubiJubell
CherubiJubell:
I like it! Give them money! They are saving the world!😄
Calling Bull
Calling Bull:
Amen in the name of Jesus.
Tomatl D&T
Tomatl D&T:
what a lie
Nickel_ Less_215
Nickel_ Less_215:
Population control. So as long as the stock is good sound legit. Can’t wait for the reply’s
annie carroll
annie carroll:
I would not take the vaccine for any reason, but especially because the information came from CNBC.
Tracie Roberts
Tracie Roberts:
No thanks. No vaccine for me. 💖
Michael H.
Michael H.:
I'm a purist.
No drugs!
Never!
Not even to prolong my life!
No thanks.
encinobalboa
encinobalboa:
Great! The health care system under Trump is actually working.